Immunization of mice with recombinant protein cobb or AsnC Confers protection against Brucella abortus infection

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Fu, Simei ^a,b   Xu, Jie ^a,b   Li, Xianbo ^a,c   Xie, Yongfei ^a,d   Qiu, Yefeng ^a   Du, Xinying ^a   Yu, Shuang ^a   Bai, Yaoxia ^a   Chen, Yanfen ^a,b   Wang, Tongkun ^a   Wang, Zhoujia ^a   Yu, Yaqing ^b   Peng, Guangneng ^c   Huang, Kehe ^d   Huang, Liuyu ^a   Wang, Yufei ^a   Chen, Zeliang ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b JILIN UNIVERSITY   (China)

^c SICHUAN AGRICULTURAL UNIVERSITY   (China)

^d NANJING AGRICULTURAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ASNC VACCINE; COBB VACCINE; COPPER ZINC SUPEROXIDE DISMUTASE; FREUND ADJUVANT; GAMMA INTERFERON; IMMUNOGLOBULIN G; LIVE VACCINE; RECOMBINANT VACCINE; S19 VACCINE; UNCLASSIFIED DRUG; ASNC PROTEIN, E COLI; BACTERIAL ANTIGEN; BRUCELLA VACCINE; COBB PROTEIN, E COLI; ESCHERICHIA COLI PROTEIN; RECOMBINANT PROTEIN; SIRTUIN; SUPEROXIDE DISMUTASE; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BRUCELLA ABORTUS; BRUCELLOSIS; CELLULAR IMMUNITY; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOKINE RELEASE; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; MOLECULAR CLONING; MOUSE; NONHUMAN; OPEN READING FRAME; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SPLEEN CELL; ANIMAL; BAGG ALBINO MOUSE; CYTOLOGY; IMMUNE SYSTEM; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; SPLEEN; T LYMPHOCYTE;

BACTERIA (MICROORGANISMS); BRUCELLA; BRUCELLA MELITENSIS BIOVAR ABORTUS; MUS;

ANIMALS; ANTIGENS, BACTERIAL; BRUCELLA ABORTUS; BRUCELLA VACCINE; BRUCELLOSIS; ESCHERICHIA COLI PROTEINS; FEMALE; IMMUNE SYSTEM; IMMUNIZATION; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; RECOMBINANT PROTEINS; SIRTUINS; SPLEEN; SUPEROXIDE DISMUTASE; T-LYMPHOCYTES; TRANS-ACTIVATORS;

EID: 84863134816     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029552     Document Type: Article

References (41)

1. Corbel MJ, (1997) Brucellosis: an overview. Emerg Infect Dis 3: 213-221.
2. Godfroid J, Cloeckaert A, Liautard JP, Kohler S, Fretin D, et al. (2005) From the discovery of the Malta fever's agent to the discovery of a marine mammal reservoir, brucellosis has continuously been a re-emerging zoonosis. Vet Res 36: 313-326.
3. Wang Y, Bai Y, Qu Q, Xu J, Chen Y, et al. (2011) The 16MΔ vjbR as an Ideal Live Attenuated Vaccine Candidate for Differentiation between Brucella Vaccination and Infection. Veterinary Microbiology.
4. Grillo MJ, Marin CM, Barberan M, de Miguel MJ, Laroucau K, et al. (2009) Efficacy of bp26 and bp26/omp31 B. melitensis Rev.1 deletion mutants against Brucella ovis in rams. Vaccine 27: 187-191.
5. Ficht TA, Kahl-McDonagh MM, Arenas-Gamboa AM, Rice-Ficht AC, (2009) Brucellosis: the case for live, attenuated vaccines. Vaccine 27 (Suppl 4): D40-43.
6. Pasquevich KA, Estein SM, Garcia Samartino C, Zwerdling A, Coria LM, et al. (2009) Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection. Infect Immun 77: 436-445.
7. Kaushik P, Singh DK, Kumar SV, Tiwari AK, Shukla G, et al. (2010) Protection of mice against Brucella abortus 544 challenge by vaccination with recombinant OMP28 adjuvanted with CpG oligonucleotides. Vet Res Commun 34: 119-132.
8. Delpino MV, Estein SM, Fossati CA, Baldi PC, Cassataro J, (2007) Vaccination with Brucella recombinant DnaK and SurA proteins induces protection against Brucella abortus infection in BALB/c mice. Vaccine 25: 6721-6729.
9. Yang Y, Yin J, Guo D, Lang X, Wang X, (2010) Immunization of mice with recombinant S-adenosyl-L-homocysteine hydrolase protein confers protection against Brucella melitensis infection. FEMS Immunol Med Microbiol 61: 159-167.
10. Schurig GG, Sriranganathan N, Corbel MJ, (2002) Brucellosis vaccines: past, present and future. Vet Microbiol 90: 479-496.
11. Ko J, Splitter GA, (2003) Molecular host-pathogen interaction in brucellosis: current understanding and future approaches to vaccine development for mice and humans. Clin Microbiol Rev 16: 65-78.
12. He Y, Vemulapalli R, Schurig GG, (2002) Recombinant Ochrobactrum anthropi expressing Brucella abortus Cu,Zn superoxide dismutase protects mice against B. abortus infection only after switching of immune responses to Th1 type. Infect Immun 70: 2535-2543.
13. Mallick AI, Singha H, Khan S, Anwar T, Ansari MA, et al. (2007) Escheriosome-mediated delivery of recombinant ribosomal L7/L12 protein confers protection against murine brucellosis. Vaccine 25: 7873-7884.
14. Al-Mariri A, (2010) Protection of BALB/c mice against Brucella melitensis 16M infection induced by vaccination with live Escherchia coli expression Brucella P39 protein. Vaccine 28: 1766-1770.
15. Kaushik P, Singh DK, Kumar SV, Tiwari AK, Shukla G, et al. (2010) Protection of mice against Brucella abortus 544 challenge by vaccination with recombinant OMP28 adjuvanted with CpG oligonucleotides. Vet Res Commun 34: 119-132.
16. Arenas GN, Staskevich AS, Aballay A, Mayorga LS, (2000) Intracellular trafficking of Brucella abortus in J774 macrophages. Infect Immun 68: 4255-4263.
17. Busso D, Delagoutte-Busso B, Moras D, (2005) Construction of a set Gateway-based destination vectors for high-throughput cloning and expression screening in Escherichia coli. Anal Biochem 343: 313-321.
18. Hong PC, Tsolis RM, Ficht TA, (2000) Identification of genes required for chronic persistence of Brucella abortus in mice. Infect Immun 68: 4102-4107.
19. Lestrate P, Dricot A, Delrue RM, Lambert C, Martinelli V, et al. (2003) Attenuated signature-tagged mutagenesis mutants of Brucella melitensis identified during the acute phase of infection in mice. Infect Immun 71: 7053-7060.
20. Haine V, Sinon A, Van Steen F, Rousseau S, Dozot M, et al. (2005) Systematic targeted mutagenesis of Brucella melitensis 16M reveals a major role for GntR regulators in the control of virulence. Infect Immun 73: 5578-5586.
21. Marchesini MI, Ugalde JE, Czibener C, Comerci DJ, Ugalde RA, (2004) N-terminal-capturing screening system for the isolation of Brucella abortus genes encoding surface exposed and secreted proteins. Microb Pathog 37: 95-105.
22. de Jong MF, Sun YH, den Hartigh AB, van Dijl JM, Tsolis RM, (2008) Identification of VceA and VceC, two members of the VjbR regulon that are translocated into macrophages by the Brucella type IV secretion system. Mol Microbiol 70: 1378-1396.
23. Edmonds MD, Cloeckaert A, Elzer PH, (2002) Brucella species lacking the major outer membrane protein Omp25 are attenuated in mice and protect against Brucella melitensis and Brucella ovis. Vet Microbiol 88: 205-221.
24. den Hartigh AB, Rolán HG, de Jong MF, Tsolis RM, (2008) VirB3 to VirB6 and VirB8 to VirB11, but not VirB7, are essential for mediating persistence of Brucella in the reticuloendothelial system. J Bacteriol 190: 4427-4436.
25. Baron C, (2006) VirB8: a conserved type IV secretion system assembly factor and drug target. Biochem Cell Biol 84: 890-899.
26. Andrews E, Salgado P, Folch H, Onate A, (2006) Vaccination with live Escherichia coli expressing Brucella abortus Cu/Zn superoxide-dismutase: II. Induction of specific CD8+ cytotoxic lymphocytes and sensitized CD4+ IFN-gamma-producing cell. Microbiol Immunol 50: 389-393.
27. Eze MO, Yuan L, Crawford RM, Paranavitana CM, Hadfield TL, et al. (2000) Effects of opsonization and gamma interferon on growth of Brucella melitensis 16M in mouse peritoneal macrophages in vitro. Infect Immun 68: 257-263.
28. Zhan Y, Cheers C, (1993) Endogenous gamma interferon mediates resistance to Brucella abortus infection. Infect Immun 61: 4899-4901.
29. Masignani V, Rappuoli R, Pizza M, (2002) Reverse vaccinology: a genome-based approach for vaccine development. Expert Opin Biol Ther 2: 895-905.
30. Mora M, Veggi D, Santini L, Pizza M, Rappuoli R, (2003) Reverse vaccinology. Drug Discov Today 8: 459-464.
31. Altindis E, Tefon BE, Yildirim V, Ozcengiz E, Becher D, et al. (2009) Immunoproteomic analysis of Bordetella pertussis and identification of new immunogenic proteins. Vaccine 27: 542-548.
32. Chen Z, Peng B, Wang S, Peng X, (2004) Rapid screening of highly efficient vaccine candidates by immunoproteomics. Proteomics 4: 3203-3213.
33. Doolan DL, Mu Y, Unal B, Sundaresh S, Hirst S, et al. (2008) Profiling humoral immune responses to P. falciparum infection with protein microarrays. Proteomics 8: 4680-4694.
34. Li B, Jiang L, Song Q, Yang J, Chen Z, et al. (2005) Protein microarray for profiling antibody responses to Yersinia pestis live vaccine. Infect Immun 73: 3734-3739.
35. Covert BA, Spencer JS, Orme IM, Belisle JT, (2001) The application of proteomics in defining the T cell antigens of Mycobacterium tuberculosis. Proteomics 1: 574-586.
36. Li B, Zhou L, Guo J, Wang X, Ni B, et al. (2009) High-throughput identification of new protective antigens from a Yersinia pestis live vaccine by enzyme-linked immunospot assay. Infect Immun 77: 4356-4361.
37. Radhakrishnan GK, Yu Q, Harms JS, Splitter GA, (2009) Brucella TIR Domain-containing Protein Mimics Properties of the Toll-like Receptor Adaptor Protein TIRAP. J Biol Chem 284: 9892-9898.
38. Gomes M, Appelberg R, (1998) Evidence for a link between iron metabolism and Nramp1 gene function in innate resistance against Mycobacterium avium. Immunology 95: 165-168.
39. Velikovsky CA, Cassataro J, Giambartolomei GH, Goldbaum FA, Estein S, et al. (2002) A DNA vaccine encoding lumazine synthase from Brucella abortus induces protective immunity in BALB/c mice. Infect Immun 70: 2507-2511.
40. Mallick AI, Singha H, Chaudhuri P, Nadeem A, Khan SA, et al. (2007) Liposomised recombinant ribosomal L7/L12 protein protects BALB/c mice against Brucella abortus 544 infection. Vaccine 25: 3692-3704.
41. Cassataro J, Pasquevich KA, Estein SM, Laplagne DA, Velikovsky CA, et al. (2007) A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination. Vaccine 25: 4437-4446.